ethyl 2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxylate | 1426521-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxylate
• 英文别名: Ethyl 2-(4-fluorophenyl)pyrazolo[1,5-A]pyridine-3-carboxylate
• CAS: 1426521-37-0
• 化学式: C₁₆H₁₃FN₂O₂
• 分子量: 284.29
• InChiKey: SSCXDUWUOYCVHA-UHFFFAOYSA-N

物化性质

• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxylate 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 20.0h， 以58 mg的产率得到2-(4-fluorophenyl)pyrazolo[1,5-c]pyridine-3-carbohydrazide
  参考文献：
  名称：

  BICYCLIC AGONISTS OF GPR131 AND USES THEREOF

  摘要：

  本公开涉及作为GPR131的激动剂或以其他方式调节其活性的化合物，以及它们在治疗各种疾病中的应用。在特定实施例中，化合物的结构由公式I给出：其中变量如本文所述。还描述了与公式I化合物的相关组合物、配方和制备方法。

  公开号：

  US20130059845A1
• 作为产物：
  描述：

  4-氟苯乙炔 在 正丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 ethyl 2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine-3-carboxylate
  参考文献：
  名称：

  SUBSTITUTED PYRAZOLES AND IMIDAZOLES AS OREXIN RECEPTOR ANTAGONISTS COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS

  摘要：

  The disclosure relates to substituted Imidazole and Pyrazole ring system derivatives of compounds that are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved or implicated. This disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  公开号：

  WO2024044351A2

文献信息

• Copper-mediated synthesis of pyrazolo[1,5-a]pyridines through oxidative linkage of C–C/N–N bonds
  作者：Darapaneni Chandra Mohan、Chitrakar Ravi、Sadu Nageswara Rao、Subbarayappa Adimurthy

  DOI：10.1039/c5ob00018a

  日期：——

  Copper-mediated synthesis of pyrazolo[1,5-a]pyridine-3-carboxylates through oxidative linkage of C–C and N–N bonds under mild reaction conditions with broad substrate scope is described.

  通过铜介导的合成，描述了在温和的反应条件下通过氧化连接C-C和N-N键来合成吡唑并[1,5-a]吡啶-3-羧酸酯，具有广泛的底物范围。
• Design, synthesis and cytotoxicity studies of novel pyrazolo[1, 5-a]pyridine derivatives
  作者：Chitrakar Ravi、Arem Qayum、Darapaneni Chandra Mohan、Shashank K. Singh、Subbarayappa Adimurthy

  DOI：10.1016/j.ejmech.2016.11.037

  日期：2017.1

  Copper–mediated synthesis of various pyrazolo[1, 5–a]pyridine-3-carboxylates has been described. The biological activities of these molecules have been evaluated against various human cancer cell lines A549 (Lung adenocarcinoma cell line), MCF-7 (Breast carcinoma cell line), HCT-116 (Colon cancer cell line), and PC-3 (Prostate cancer cell line) through SRB assay. Compound 247 led to accumulation MCF-7 cells

  已经描述了铜介导的各种吡唑并[1，5–a]吡啶-3-羧酸酯的合成。已经评估了这些分子对各种人类癌细胞系A549（肺腺癌细胞系），MCF-7（乳腺癌细胞系），HCT-116（结肠癌细胞系）和PC-3（前列腺癌）的生物学活性。细胞系）通过SRB分析。化合物247导致MCF-7细胞在G1期积累，并揭示了其在有丝分裂细胞周期进程中的重要作用。
• US9593109B2
  申请人：——

  公开号：US9593109B2

  公开（公告）日：2017-03-14
• [EN] BICYCLIC AGONISTS OF GPR131 AND USES THEREOF<br/>[FR] AGONISTES BICYCLIQUES DE GPR131 ET LEURS UTILISATIONS
  申请人：METABOLEX INC

  公开号：WO2013032939A1

  公开（公告）日：2013-03-07

  The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.
• BICYCLIC AGONISTS OF GPR131 AND USES THEREOF
  申请人：SONG Jiangao

  公开号：US20130059845A1

  公开（公告）日：2013-03-07

  The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.

  本公开涉及作为GPR131的激动剂或以其他方式调节其活性的化合物，以及它们在治疗各种疾病中的应用。在特定实施例中，化合物的结构由公式I给出：其中变量如本文所述。还描述了与公式I化合物的相关组合物、配方和制备方法。